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Abstract Diversity in lifestyles and socioeconomic status
among European populations, and recent socio-political and
economic changes in transitional countries, may affect
changes in adiposity. We aimed to determine whether
change in the prevalence of obesity varies between the
socio-politically transitional North-East European (Łódź,
Poland; Szeged, Hungary; Tartu, Estonia), and the non-
transitional Mediterranean (Santiago de Compostela,
Spain; Florence, Italy) and North-West European (Leuven,
Belgium; Malmö, Sweden; Manchester, UK) cities. This
prospective observational cohort survey was performed
between 2003 and 2005 at baseline and followed up
between 2008 and 2010 of 3369 community-dwelling men
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aged 40–79 years. Main outcome measures in the present
paper included waist circumference, body mass index and
mid-upper arm muscle area. Baseline prevalence of waist
circumference ≥ 102 cm and body mass index ≥ 30 kg/m2,
respectively, were 39.0, 29.5 % in North-East European
cities, 32.4, 21.9 % in Mediterranean cities, and 30.0,
20.1 % in North-West European cities. After median 4.3
years, men living in cities from transitional countries had
mean gains in waist circumference (1.1 cm) and body mass
index (0.2 kg/m2), which were greater than men in cities
from non-transitional countries (P= 0.005). North-East
European cities had greater gains in waist circumference
(1.5 cm) than in Mediterranean cities (P< 0.001). Over 4.3
years, the prevalence of waist circumference ≥ 102 cm had
increased by 13.1 % in North-East European cities, 5.8 % in
the Mediterranean cities, 10.0 % in North-West European
cities. Odds ratios (95 % confidence intervals), adjusted for
lifestyle factors, for developing waist circumference ≥ 102
cm, compared with men from Mediterranean cities, were
2.3 (1.5–3.5) in North-East European cities and 1.6
(1.1–2.4) in North-West European cities, and 1.6 (1.2–2.1)
in men living in cities from transitional, compared with
cities from non-transitional countries. These regional dif-
ferences in increased prevalence of waist circumference ≥
102 cm were more pronounced in men aged 60–79 years
than in those aged 40–59 years. Overall there was an
increase in the prevalence of obesity (body mass index ≥
30 kg/m2) over 4.3 years (between 5.3 and 6.1 %) with no
significant regional differences at any age. Mid-upper arm
muscle area declined during follow-up with the greatest
decline among men from North-East European cities. In
conclusion, increasing waist circumference is dissociated
from change in body mass index and most rapid among men
living in cities from transitional North-East European
countries, presumably driven by economic and
socio–political changes. Information on women would also
be of value and it would be of interest to relate the changes
in adiposity to dietary and other behavioural habits.
Keywords Obesity ● Fat distribution ● Environment ● Body
mass index ● Waist circumference ● Health promotion
Introduction
Obesity is the major driver for type 2 diabetes mellitus,
premature cardiovascular disease, the metabolic syndrome
and a host of other secondary health complications [1, 2].
Furthermore recent studies indicate that obesity is a risk
factor of cancer incidence at several cancer sites [3, 4].
Recognising the scale of consequent disability and health-
care costs, obesity prevention has been declared as a major
public health priority in many countries [5]. The global
obesity epidemic, over the last 30–40 years, can only have
emerged through changes in environmental and social fac-
tors which have resulted in poor diet (high energy/low
nutrient-density foods and meals), and physical inactivity
[6]. Previously largely restricted to the wealthy, social
deprivation has emerged as a powerful driver of obesity in
the post-industrial period. Familial patterning is well
recognised, but classical genetics plays only a small part [7].
It is increasingly recognised that shared environments
within families serve a dual role, not only producing con-
ditions which favour immediate positive energy balance,
but also changing susceptibility to weight gain and obesity
throughout the lifespan through epigenetic modifications,
altering gene expressions after exposure to adverse envir-
onment in utero or in early life [8].
Recent cross-sectional analyses of European Male Age-
ing Study (EMAS) baseline data have shown that obesity
was significantly associated with social and lifestyle factors
including smoking status, physical activity level and edu-
cation attainment in European men aged 40–79 years [9].
This EMAS cohort comprises populations from eight major
cities, covering the Mediterranean (Spain and Italy), North-
West (NW) (Belgium, Sweden and England) and North-
East (NE) (Poland, Hungary and Estonia) European regions,
which are diverse in lifestyle and dietary habits [10–12].
These eight cities also embody the contrasting socio-
political systems between transitional and non-transitional
regions in Europe [13]. Lifestyle and dietary habits in many
transitional countries in NE Europe have recently been
increasingly more westernized, particularly among younger
people, practising an increase in consumption of calorie-
dense/poor-nutrient diet, replacing healthy native diet of
fruit, vegetables, nuts and grains [14]. A survey of adults
aged 18–74 in the European Union conducted between
2006 and 2010 showed the prevalence of obesity (body
mass index, BMI ≥ 30 kg/m2) in the EMAS regions was
11.3 % in Italy, 17.0 % in Spain, 13.3 % in Belgium, 22.1 %
in the UK, 17.3 % in Poland, 21.4 % in Hungary and 16.0 %
in Estonia [15]. More recent WHO data on adult (≥18 years)
male obesity prevalence in 2014 show 22.8 % in Spain,
20.4 % in Italy, 22.3 % in Belgium, 22.5 % in Sweden,
26.9 % in UK, 24.6 % in Poland, 24.4 % in Hungary and
22.2 % in Estonia [16]. A large cross-country survey of
22,777 Europeans aged over 50 years in 2004 suggested
that regional differences in prevalence of obesity were not
explained by socio-demographic differences. The authors
suggested diet culture, physical activity and other lifestyle
behaviours may be the contributing factors [17]. These data
are though based on cross-sectional surveys, with variable
response rates and representativeness. Data in EMAS was
collected in a standardised way across the eight countries,
with relatively high response rates and permitted long-
itudinal comparison of changes in the prevalence of obesity
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and body fat distribution, indicated by BMI and waist cir-
cumference (WC), in diverse regions of the European
Union. We hypothesised that changes in the prevalence of
obesity may be greater in cities from the transitional
countries from NE Europe than cities from countries in the
Mediterranean and NW Europe.
Methods
Participants and study design
The study design and recruitment strategy for EMAS have
been described previously [18, 19]. Briefly, an age-stratified
sample of 3369 men aged 40–79 (mean± SD: 60± 11)
years was recruited randomly from population registers in
eight European centres, five from non-transitional (Flor-
ence, Italy; Leuven, Belgium; Malmö, Sweden; Manchester,
UK; Santiago de Compostela, Spain) and three from tran-
sitional countries (Łódź, Poland; Szeged, Hungary; Tartu,
Estonia). Participants were assessed at baseline (2003–05)
and a median of 4.3 (range 3.0–5.7) years later at follow-up
survey (2008–10) [18, 19]. Ethical approval for the study
was obtained in accordance with local requirements in each
centre. All participants provided written informed consent.
Lifestyle, socio–economic history and anthropometry
Participants answered questions about lifestyle habits
(smoking, alcohol consumption, physical activity) and
socioeconomic status (education level and employment
status). Body weight and height were measured by elec-
tronic scales (SECA, Hamburg, Germany) and stadiometer
(Holtain, Crymych, UK) and BMI was calculated as weight/
height2 (kg/m2). WC was measured at the level between the
lowest ribs and anterior suprailiac crest and mid-upper arm
circumference (MUAC) at midpoint between the acromion
and olecranon using non-stretchable tape measure, and tri-
ceps skinfold thickness in mm at the MUAC level using
skinfold calipers (Holtain, Crymych, UK) [20]. Physical
function was assessed using Physical Activity Scale for the
Elderly (PASE) questionnaire score. Mid-upper arm muscle
area was estimated from the equation: MUAC – (3.14 ×
triceps skinfold thickness) [21].
Statistical analysis
Statistical analyses were conducted using STATA SE ver-
sion 13.1 (Stata Corp, College Station, TX, USA). Indivi-
duals were categorised according to their WC ‘Action
Levels’ (<94, 94–101.9 and ≥102 cm) [22] or BMI (<25,
25–29.9 and ≥30 kg/m2) [23]. For the purpose of this ana-
lysis, peak education attainment level was classified as
below high school, or college/university; employment status
as either currently in or not in employment; smoking status
as never, former or current; and alcohol consumption as non-
drinkers, infrequent alcohol drinkers (1–4 days/week) or
frequent alcohol drinkers (≥5 days/week). Because we did
not have reliable information on retirement status, we deci-
ded to classify subjects into employment and non-
employment groups for men below 65 years old (working
age in most countries). Physical activity levels were classi-
fied according to quartiles of PASE questionnaire score [9].
Development of large WC and high BMI
Changes between all BMI and WC categories, in both
directions over a median 4.3 years were analysed. The
development of, or the new occurrence of obesity (WC ≥
102 cm or BMI ≥ 30 kg/m2) was defined as new cases who
moved upwards from any lower WC or BMI categories.
Those who were obese at baseline were not included in the
analysis. For new development of the moderately elevated
middle categories, only subjects who moved upwards from
the lowest category were included, i.e., those who lost
weight from the highest WC category or highest BMI
category into middle category were not considered as new
cases.
Analysis of variance (ANOVA) was used to assess the
statistical significance of changes in WC or BMI (con-
tinuous variables) between study groups. Bonferroni
multiple-comparison test was used for simultaneous esti-
mation of paired group differences. Logistic regression
analysis was used to determine whether the risk of devel-
oping obesity varied by cities, with Santiago de Compos-
tela, Spain as the referent group; by region, with
Mediterranean cities as the referent group and by transi-
tional region status with the cities from non-transitional
countries as referent. Analyses were further repeated sepa-
rately in two age categories to assess whether the incidence
of obesity were different for men aged 40–59 years and
60–79 years. Data were presented both unadjusted and
adjusted for baseline socioeconomic status and lifestyle
factors mentioned above.
Results
Figure 1a shows that at baseline, the prevalences of
WC ≥ 102 cm and BMI ≥ 30 kg/m2, respectively, were
highest among men living in Szeged, Hungary (45.8 and
35.2 %) and Tartu, Estonia (41.1 and 32.9 %) and lowest
among men living in Florence, Italy (25.9 and 17.1 %) and
Leuven, Belgium (28.4 and 19.8 %). Within each of these
cities, these prevalences were higher among men over
60 than those under 60 years-old. Regionally, the baseline
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prevalences of WC ≥ 102 cm and BMI ≥ 30 kg/m2, respec-
tively, were 32.4 and 21.9 % in Mediterranean cities (San-
tiago de Compostela and Florence) and similarly 30.0 and
20.1 % in NW European cities (Leuven, Malmö and Man-
chester), while the respective values were almost 10 %
higher (P< 0.001) in cities from the transitional NE Eur-
opean (Łódź, Szeged, and Tartu) region (39.0 and 29.5 %).
Changes between all BMI and WC categories over a
median 4.3 years are shown in Table 1. Increase in pre-
valence or development of WC ≥ 102 cm was 12.3 %
(266/2148) or BMI ≥ 30 kg/m2 was 5.9 % (149/2499). New
development of the moderately elevated middle categories
of WC 94–101 cm was 16.9 % (194/1142) or BMI 25–29
kg/m2 was 15.1 % (132/870). Those who lost weight from
the highest WC (≥102 cm: 124/1171, 10.5 %) category or
highest BMI (≥30 kg/m2: 77/814, 9.4 %) category into
middle category were not considered as new cases. There
were significantly greater proportions of men living in NE
European cities (transitional regions) gaining WC from
lower categories (<94 cm and 94–101 cm) to highest cate-
gory (≥102 cm) than men living in Mediterranean cities and
in NW European cities (non-transitional countries). Con-
versely significantly greater proportions of men living in
cities from non-transitional countries had WC reduced from
moderate category (94–101 cm) to lowest category. In
contrast to observations on changes in WC, there were no
regional differences in the gains/reductions of BMI (data
not shown).
Compared to men living in Santiago de Compostela, who
had the lowest rise in WC, men living in all three cities from
transitional countries showed significantly greater rises in
mean WC (1.6–2.0 cm), as did men in Leuven, but not in
Malmö or Manchester from the non-transitional region
(Table 2A). Men living in cities from the transitional
countries had greater gain in WC (1.1 cm) (Table 2A) and in
BMI (0.2 kg/m2) (Table 2B) than those in cities from the
non-transitional countries, and a significantly greater gain in
WC (1.5 cm) (but not BMI) than men living in the Medi-
terranean cities. For both age groups below and above 60
years, compared with men living in Mediterranean cities,
those living in NE European cities lost significantly more
lean body tissue, estimated from MUAC (Table 2C).
Figure 2a shows that in all men aged 40–79 years, over
4.3 years, the development of WC ≥ 102 cm was lowest at
5.8 % in Mediterranean cities, 10.0 % in NW European
cities and highest (13.1 %) in NE European cities. Further
analysis by age groups revealed that these regional differ-
ences in developing large WC were more pronounced in
men aged 60–79 compared with those aged 40–59 years.
There were no regional differences in changes in prevalence
of BMI ≥ 30 kg/m2 (Fig. 2b).
Table 3 shows that compared with men living in Medi-
terranean cities, adjusted odds ratios for developing a WC ≥
102 cm were 1.6-fold greater in men living in NW European
cities and 2.3-fold greater in men living in NE European
cities. Compared with men living in cities from non-
transitional countries, the odds ratio for developing WC ≥
102 cm was 1.6 fold greater in men living in cities from the
transitional countries. There were no regional differences in
odds ratios for developing a BMI ≥ 30 kg/m2. Odds ratios
for regional differences in developing a large WC remained
significant when analysed by age group, and were greater in
men aged 60–79 than 40–59 (Table 4A). There were no
regional differences in developing a BMI ≥ 30 kg/m2 in
either age group (Table 4B).
We have also analysed changes in the intermediate
categories of adiposity (results not shown), there were only
differences in those whose WC rose from the lowest to
(39.4)
(25.9)
(38.2)
(28.4) (32.0)
(31.9)
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b
Fig. 1 Baseline prevalence men with large waist circumference (a) or
with high BMI (b) in eight European cities
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moderately elevated (94–101.9 cm) between Santiago de
Compostela and Malmö, (decrease). Compared with San-
tiago de Compostela, the adjusted odds ratios in increase in
prevalence of moderately high BMI (25–29.9 kg/m2) were
increased in Florence, Leuven, Malmö, Łódź and Szeged.
Discussion
We found that WC, a marker of secondary disease risk
through its correlation with total body fat and with central
fat accumulation in thinner subjects [24], rose substantially
Table 2B A 4.3-year change in BMI in eight European cities, and differences in gain in BMI between men living in cities from the Mediterranean,
NW and NE Europe, and between men living in non-transitional (Mediterranean + NW Europe) and cities from transitional countries (NE Europe)
n Baseline mean
(SD) of BMI
Absolute (%)
change
ANOVA for differences between cities and groups of cities in
different regions
Between
individual cities
Between
Regions
Between transitional status
(non-transitional/transitional)
Mediterranean: Santiago de
Compostela, Spain
272 28.2 (3.7) −0.02 (−0.08) Referent Referent Referent
Mediterranean: Florence, Italy 346 27.0 (3.6) +0.23 (+1.05) +0.25
NW Europe: Leuven, Belgium 372 27.1 (3.9) +0.10 (+0.46) +0.12 −0.08
NW Europe: Malmö, Sweden 344 27.2 (3.9) +0.16 (+0.65) +0.18
NW Europe: Manchester, UK 300 27.6 (3.6) −0.15 (−0.54) −0.13
NE Europe: Łódź Poland 310 27.5 (3.8) +0.56 (+2.10) +0.57* +0.15 +0.20*
NE Europe: Szeged, Hungary 347 28.7 (4.3) +0.16 (+0.68) +0.18
NE Europe: Tartu, Estonia 299 28.5 (5.0) +0.11 (+0.42) +0.13
aP< 0.001 aP= 0.01 aP= 0.005
Bold values indicate “statistical significant” results
ANOVA analysis of variance, BMI body mass index, SD standard deviation
*P< 0.05
a Bonferroni multiple-comparison test. Differences from referent group
Table 2A A 4.3-year change in WC in eight European cities, and differences in gain in WC between men living in cities from the Mediterranean,
NW and NE Europe, and between men living in cities from non-transitional (Mediterranean+NW Europe) and cities from transitional countries
(NE Europe)
n Baseline mean
(SD) of WC
Absolute (%)
change
ANOVA for differences between cities and groups of cities in
different regions
Between
individual cities
Between
Regions
Between transitional status
(non-transitional/transitional)
Mediterranean: Santiago de
Compostela, Spain
267 99.0 (9.5) +0.22 (+0.25) Referent Referent Referent
Mediterranean: Florence, Italy 351 96.2 (9.5) +0.85 (+0.97) +0.63
NW Europe: Leuven, Belgium 381 96.2 (11.2) +2.02 (+2.18) +1.80* +0.62
NW Europe: Malmö, Sweden 356 99.9 (10.5) +0.65 (+0.69) +0.43
NW Europe: Manchester, UK 312 97.6 (9.8) +0.84 (+0.90) +0.62
NE Europe: Łódź Poland 310 98.5 (10.2) +2.22 (+2.36) +1.99* +1.50* +1.10*
NE Europe: Szeged, Hungary 347 101 (11.7) +1.79 (+1.92) +1.57*
NE Europe: Tartu, Estonia 296 99.3 (13.4) +2.27 (+2.36) +2.05*
aP< 0.001 aP< 0.001 aP= 0.005
Bold values indicate “statistical significant” results
ANOVA analysis of variance, SD standard deviation, WC waist circumference
*P< 0.05
a Bonferroni multiple-comparison test. Differences from referent group
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over 4.3 years. The prevalence of WC ≥ 102 cm (indicating
high risk of metabolic disease) [1, 2], increased most in
cities from NE Europe, followed by cities from NW Europe
and lowest in cities from the Mediterranean. These regional
differences in rising WC were most pronounced in men
aged 60–79 years. While BMI rose over the study period,
there were no regional differences in the rises in prevalence
of high BMI, nor was there an age trend. Increased central
fat accumulation among men living in cities from NE
European was accompanied by significant loss of mid-upper
arm muscle area.
Large WC indicates an increase in the metabolically
active intra-abdominal fat which is associated with specific
clusters of symptoms, secondary metabolic syndrome and
chronic diseases including diabetes, hypertension and car-
diovascular disease [1, 2]. These conditions are exacerbated
by adverse lifestyle factors such as smoking, poor diet and
physical inactivity which tend to co-exist with obesity in
post-industrial communities [25]. Given the already-high
baseline prevalence of large WC in men living in the
transitional region, their greater risk of developing large
WC over the study period is likely to herald many down-
stream health complications.
These data suggest that the rising adiposity with age,
especially of WC (but less of BMI), appears to be more
pronounced in transitional countries presumably related to
the recent and continuing socio–political and economic
changes. Our data were adjusted for a number of socio-
demographic and lifestyle factors therefore the results may
reflect the obesogenic social conditions due at least in part
to sedentary lifestyles and consumption of energy-dense
food [14]. We have also performed unadjusted analyses and
found that differences between countries and between
regions were slightly stronger than adjusted data (results not
shown). However, the dissociation between WC and BMI
changes may point towards an increase in individual sus-
ceptibility to weight gain and cardiometabolic risk. The lack
of regional differences in BMI may be accounted for by the
concurrently greater loss of mid-upper arm muscle area,
which may indicate a general loss of lean body tissue, in NE
European men. Age-related muscle atrophy is the central
feature of sarcopenic syndrome, a condition associated with
frailty and poor health [26, 27]. Sarcopenic obesity, a
condition associated with excess energy consumption,
sedentary lifestyle and chronic illnesses [28], is associated
with even worse health outcomes [29]. We should empha-
size that changes in adiposity and mid-upper arm muscle
area in the present study were calculated on the whole
group, rather than individual, basis.
Mackenbach et al. [12] have previously observed
increased mortality in lower economic status sectors of
Europe, most marked in Eastern European countries. In
contrast, in Mediterranean countries which have been more
socially and culturally stable for many decades [30], people
have continued to consume traditional Mediterranean diets
characterised by fibre-rich fruit, vegetables legumes and
cereals, more fish and poultry than red meat, and moderate
alcohol intake [31]. This diet is rich in monounsaturated
fatty acids and in micronutrients with anti-inflammatory
[32] and antioxidant properties [33]. Large prospective
studies have shown that adherence to Mediterranean diet
leads to a significant reduction in WC [34–36] and BMI
[37], consistent with evidence which links Mediterranean
diets to lower cardiovascular risk [34].
The present study also showed that developing a large
WC was significantly more likely in cities from NW Eur-
opean than in cities from Mediterranean countries. This
difference within the non-transitional zone suggests that diet
and lifestyle factors are probably more influential than
socioeconomic differences as risk factors for increased
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central fat accumulation, since NW European countries
have higher gross national income per capita than Medi-
terranean countries [38].
In our study, regional differences in the development of
large WC continued to persist after adjustments (but the
adjustments did attenuate the ORs to some/small extent) for
lifestyle factors including smoking and physical activity and
socioeconomic status including educational attainment level
and employment status. It is therefore likely that other
factors contribute to these differences. There is a body of
evidence indicating that in utero exposure to maternal fac-
tors such as obesity, poor diet and smoking can modify gene
expression though DNA methylation and histones, which
can exacerbate obesity in later life [8, 39]. It is now known
that these epigenetic changes can be inherited, and their
effects continue over several generations [40]. In principle,
epigenetic effects may be harmful or protective. In keeping
with other studies of epigenetic effects from smoking [41,
42], we have demonstrated previously that maternal
smoking associates with future adult adiposity and cardio-
vascular risk [43]. Parental smoking history was not col-
lected in EMAS but transitional countries had the highest
prevalence of smokers and ex-smokers at baseline [9] and
smoking is strongly retained as an inter-generational trait
within families [43]. Thus exposure to parental tobacco
smoke in early life or in utero may have driven some of the
harmful epigenetic changes. It remains possible that the
relatively stable Mediterranean diet, and lifestyle confers
protective epigenetic effects, or that changes in social and
domestic conditions during politico–economic strife induce
stress and thus harmful epigenetic changes. The latter
hypothesis may also apply to the increased rates of central
adiposity, cardiovascular and metabolic diseases seen ubi-
quitously amongst migrant populations [44] which tend to
live under chronic stress. Evidence from animal studies
demonstrates adverse epigenetic changes after exposure to
stress in pregnancy [45].
Maternal smoking, including passive smoking, and stress
during pregnancy cause poor intra-uterine growth and low
birthweight, which predisposes individuals to increased
intra-abdominal/central fat accumulation and cardio-
metabolic risk in adult life [46, 47], particularly when
exposed to abundant high-energy foods [48]. Rates of low
birthweight (<2500 g) were similar, ranging between 5 and
9 % among the eight countries in the present study in 2000
[49]. Birthweight data are not available for the period
1923–1963 when subjects in the present study were born,
but that was a time of greater economic austerity and stress
in the transitional countries, so birthweights might have
been lower than in non-transitional countries.
Inevitably there are limitations to the interpretation of
these data. However, the present study has particular
strengths in its prospective design and detailed
contemporary assessment of contrasting populations in
Europe, capturing a period of considerable social change in
some European countries. The study samples were repre-
sentative locally, but not necessarily nationally. We enrolled
mainly Caucasian men with a study response rate of 41 %,
which could limit generalizability. Although the EMAS
database is large, allowing assessment of many aspects of
male aging, there are pieces of information which could not
reliably be collected, such as birthweight and dietary
assessment, and others where risk of participant-fatigue
meant that self-reported information could not be com-
plemented by measured data, such as physical activity by
odometers and dietary intake. The statistical methods
employed were robust, and data were adjusted where pos-
sible for potential confounders and co-variates, but residual
confounding is always possible, particularly in a cross-
cultural study of this kind where measures of socio-
economic status may vary. Information on women would
also be of value and it would be of interest to relate the
changes in adiposity to dietary and other behavioural habits.
In conclusion, while weight and BMI is generally rising
among European men, WC are increasing more rapidly,
particularly in countries undergoing socio–economic and
political transition. This changing body shape profile pre-
dicts greater future burdens from cardio-metabolic diseases
and, according to recent studies, from cancer [3, 4].
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